{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:34:12Z","timestamp":1793054052866,"version":"4.5.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","funder":[{"name":"Intramural Research Program of the Division of Cancer Epidemiology and Genetics of the US National Cancer Institute","id":[{"id":"https:\/\/ror.org\/00vkwep27","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Institutes of Health and the Institute of Cancer Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Evaluating breast cancer mortality by estrogen receptor status can help inform strategies to reduce the US breast cancer burden. We used Surveillance, Epidemiology, and End Results 17 registries to calculate age-standardized breast cancer incidence-based mortality rates per 100\u2009000 person-years from 2009 to 2022 by estrogen receptor status (positive and negative) and compared with incidence and 5-year relative survival. We estimated trends using average annual percent change. For estrogen receptor\u2013positive breast cancers, incidence-based mortality rates marginally increased from 2009 (16.6) to 2014 (17.2) and then decreased by 2022 (15.2) (2009-2022: average annual percent change = \u22120.65%, 95% CI = \u22121.35% to 0.05%; 2014-2022: average annual percent change = \u22121.53%, 95% CI = \u22121.88% to \u22121.19%). Incidence rates decreased then increased again, with small increases in survival. For estrogen receptor\u2013negative breast cancers, incidence-based mortality rates decreased statistically significantly decreased (2009\u2009[9.6]; 2022\u2009[6.4]; average annual percent change = \u22123.33%, 95% CI = \u22124.17% to \u22122.48%) in parallel with declining incidence rates and significant survival improvements. In 2022, estrogen receptor\u2013positive breast cancers accounted for 5 times more cases and 2 times more deaths than estrogen receptor\u2013negative; despite effective therapies, estrogen receptor\u2013positive mortality did not have substantial declines, indicating public health opportunities to reduce the population burden of breast cancer mortality.<\/jats:p>","DOI":"10.1093\/jnci\/djag347","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:31:09Z","timestamp":1790508669000},"source":"Crossref","is-referenced-by-count":0,"title":["Trends in US breast cancer mortality by estrogen receptor status"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8891-4437","authenticated-orcid":false,"given":"Jacqueline B","family":"Vo","sequence":"first","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD,","place":["United States"]},{"name":"Nell Hodgson Woodruff School of Nursing, Emory University , Atlanta, GA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma R","family":"Mitra","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macy E","family":"Corley","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith S","family":"Shiels","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittny C","family":"Davis Lynn","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6537-1481","authenticated-orcid":false,"given":"Lene H S","family":"Veiga","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinani","family":"Jayasekera","sequence":"additional","affiliation":[{"name":"Division of Intramural Research, National Institute on Minority Health and Health Disparities , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie T Y","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen L","family":"Gierach","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology and Genetics, National Cancer Institute , Rockville, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7332-8387","authenticated-orcid":false,"given":"Amy","family":"Berrington de Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Division of Genetics and Epidemiology, The Institute of Cancer Research , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"2026102617404277900_djag347-B1","volume-title":"Breast Cancer Facts & Figures 2022-2024","author":"American Cancer Society","year":"2022"},{"key":"2026102617404277900_djag347-B2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/0895-4356(94)90089-2","article-title":"A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer","volume":"47","author":"Chu","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"2026102617404277900_djag347-B3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/aje\/kwr512","article-title":"Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer","volume":"176","author":"Howlader","year":"2012","journal-title":"Am J Epidemiol"},{"key":"2026102617404277900_djag347-B4","doi-asserted-by":"publisher","author":"Davis Lynn","DOI":"10.1093\/jnci\/djab186"},{"key":"2026102617404277900_djag347-B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djv159","article-title":"Estrogen receptor status and the future burden of invasive and in situ breast cancers in the United States","volume":"107","author":"Rosenberg","year":"2015","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2026102617404277900_djag347-B6","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/jnci\/djr257","article-title":"Incidence of breast cancer in the United States: current and Future Trends","volume":"103","author":"Anderson","year":"2011","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2026102617404277900_djag347-B7","author":"US Census Bureau","year":"2022"},{"key":"2026102617404277900_djag347-B8","author":"Cho"},{"key":"2026102617404277900_djag347-B9","volume-title":"Instructions to IBM 650 Programmers in Processing Survival Computations","author":"Ederer","year":"1959"},{"key":"2026102617404277900_djag347-B10","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/jnci\/djad086","article-title":"Interpreting cancer incidence trends: challenges due to the COVID-19 pandemic","volume":"115","author":"Mariotto","year":"2023","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2026102617404277900_djag347-B11","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1200\/JCO.2006.09.2106","article-title":"Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis","volume":"25","author":"Jatoi","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026102617404277900_djag347-B12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10549-022-06561-z","article-title":"Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016","volume":"193","author":"Bowles","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2026102617404277900_djag347-B13","doi-asserted-by":"publisher","first-page":"e263529","DOI":"10.1001\/jamanetworkopen.2026.3529","article-title":"Trends in mammography use among women aged 40 to 74 years in the US, 2002-2022","volume":"9","author":"Al Hasan","year":"2026","journal-title":"JAMA Netw Open"},{"key":"2026102617404277900_djag347-B14","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"2026102617404277900_djag347-B15","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ejca.2017.08.031","article-title":"Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004-2013): amassing data from independent Western populations provide etiologic clues","volume":"86","author":"Mullooly","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026102617404277900_djag347-B16","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1093\/jnci\/djae172","article-title":"Risk factors for breast cancer subtypes by race and ethnicity: a scoping review","volume":"116","author":"Hurson","year":"2024","journal-title":"JNCI J Natl Cancer Inst"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag347\/71523062\/djag347.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag347\/71523062\/djag347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:40:47Z","timestamp":1793050847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article\/doi\/10.1093\/jnci\/djag347\/8853823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":16,"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag347","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"djag347"}}